<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Laser Peripheral Iridotomy - EyeWiki</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"mdy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"ZAVjWRTfA1NttscBT3SLAgAAAAY","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Laser_Peripheral_Iridotomy","wgTitle":"Laser Peripheral Iridotomy","wgCurRevisionId":87678,"wgRevisionId":87678,"wgArticleId":8550,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Articles","Glaucoma"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Laser_Peripheral_Iridotomy","wgRelevantArticleId":8550,"wgIsProbablyEditable":!1,"wgRelevantPageIsProbablyEditable":!1,"wgRestrictionEdit":[],"wgRestrictionMove":[],
"sdgDownArrowImage":"/w/extensions/SemanticDrilldown/skins/down-arrow.png","sdgRightArrowImage":"/w/extensions/SemanticDrilldown/skins/right-arrow.png","wgCiteDrawerEnableDesktop":!1,"wgCiteDrawerEnableMobile":!0,"wgCiteDrawerTheme":"dark","wgPageFormsTargetName":null,"wgPageFormsAutocompleteValues":[],"wgPageFormsAutocompleteOnAllChars":!1,"wgPageFormsFieldProperties":[],"wgPageFormsCargoFields":[],"wgPageFormsDependentFields":[],"wgPageFormsCalendarValues":[],"wgPageFormsCalendarParams":[],"wgPageFormsCalendarHTML":null,"wgPageFormsGridValues":[],"wgPageFormsGridParams":[],"wgPageFormsContLangYes":null,"wgPageFormsContLangNo":null,"wgPageFormsContLangMonths":[],"wgPageFormsHeightForMinimizingInstances":800,"wgPageFormsShowOnSelect":[],"wgPageFormsScriptPath":"/w/extensions/PageForms","edgValues":[],"wgPageFormsEDSettings":null,"wgAmericanDates":!0,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},"srfFilteredConfig":null,
"wgEditSubmitButtonLabelPublish":!1};RLSTATE={"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","mediawiki.ui.button":"ready","skins.chameleon":"ready","zzz.ext.bootstrap.styles":"ready","mediawiki.toc.styles":"ready","ext.CookieWarning.styles":"ready","oojs-ui-core.styles":"ready","oojs-ui.styles.indicators":"ready","mediawiki.widgets.styles":"ready","oojs-ui-core.icons":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.srf.styles":"ready","ext.smw.style":"ready","ext.smw.tooltip.styles":"ready"};RLPAGEMODULES=["ext.smw.style","ext.smw.tooltips","ext.cite.ux-enhancements","smw.entityexaminer","site","mediawiki.page.startup","mediawiki.page.ready","mediawiki.toc","ext.citedrawer.main","ext.CookieWarning","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.eyeWiki","ext.eyeWiki.slideshow","sentry.init","ext.bootstrap.scripts"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.CookieWarning.styles%7Cext.cite.styles%7Cext.visualEditor.desktopArticleTarget.noscript%7Cmediawiki.toc.styles%7Cmediawiki.ui.button%7Cmediawiki.widgets.styles%7Coojs-ui-core.icons%2Cstyles%7Coojs-ui.styles.indicators%7Cskins.chameleon%7Czzz.ext.bootstrap.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.smw.style%7Cext.smw.tooltip.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.srf.styles&amp;only=styles&amp;skin=chameleon"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=chameleon"></script>
<style>#mw-indicator-mw-helplink {display:none;}</style>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=chameleon"/>
<meta name="generator" content="MediaWiki 1.35.8"/>
<meta name="description" content="Laser peripheral iridotomy (also described as ‘laser iridotomy’ or simply termed &#039;iridotomy&#039;) is a medical procedure which uses a laser device to create a hole in the iris, thereby allowing aqueous humor to traverse directly from the posterior to the anterior chamber and, consequently, relieve a pupillary block.&amp;#91;1&amp;#93;&amp;#91;2&amp;#93;&amp;#91;3&amp;#93; It is commonly used to treat a wide range of clinical conditions, encompassing primary angle‐closure glaucoma, primary angle closure (narrow angles and no signs of glaucomatous optic neuropathy), patients who are primary angle‐closure suspects (patients with reversible obstruction) and even eyes with secondary causes of iridocorneal angle-closure.&amp;#91;1&amp;#93;"/>
<meta name="date" content="2022-12-24"/>
<meta name="WT.seg_1" content="0"/>
<meta name="google-site-verification" content="mtQvMIGqpWB4oyYM5mux15MHU-3qWI0bWtyRa2b5rlk"/>
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/>
<link rel="alternate" type="application/rdf+xml" title="Laser Peripheral Iridotomy" href="/w/index.php?title=Special:ExportRDF/Laser_Peripheral_Iridotomy&amp;xmlmime=rdf"/>
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="EyeWiki (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="https://eyewiki.org/w/api.php?action=rsd"/>
<link rel="preconnect" href="https://fonts.gstatic.com">
<link href="https://fonts.googleapis.com/css2?family=Lato:ital,wght@0,400;0,700;1,400&display=swap" rel="stylesheet">
<!-- Favicons MEYE-108 -->
<link rel="apple-touch-icon" sizes="120x120" href="/w/extensions/EyeWiki/favicons/apple-touch-icon.png">
<link rel="icon" type="image/png" sizes="32x32" href="/w/extensions/EyeWiki/favicons/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="16x16" href="/w/extensions/EyeWiki/favicons/favicon-16x16.png">
<link rel="manifest" href="/w/extensions/EyeWiki/favicons/site.webmanifest">
<link rel="mask-icon" href="/w/extensions/EyeWiki/favicons/safari-pinned-tab.svg" color="#603cba">
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico">
<meta name="msapplication-TileColor" content="#603cba">
<meta name="msapplication-config" content="/w/extensions/EyeWiki/favicons/browserconfig.xml">
<meta name="theme-color" content="#ffffff">
<script> window.interdeal = { "sitekey": "81c701489fb8bb4ab90ca1cb0931f9c5", "Position": "Left", "Menulang": "EN", "domains": { "js": "https://cdn.equalweb.com/", "acc": "https://access.equalweb.com/" }, "btnStyle": { "vPosition": [ "80%", null ], "scale": [ "0.8", "0.8" ], "color": { "main": "#1876c9" }, "icon": { "type": 1, "outline": false } } }; (function(doc, head, body){ var coreCall = doc.createElement('script'); coreCall.src = 'https://cdn.equalweb.com/core/4.3.8/accessibility.js'; coreCall.defer = true; coreCall.integrity = 'sha512-u6i35wNTfRZXp0KDwSb3TntaIKI2ItCt/H/KcYIsBeVbaVMerEQLBnU5/ztfBg9aSW1gg7AN4CqCu9a455jkUg=='; coreCall.crossOrigin = 'anonymous'; coreCall.setAttribute('data-cfasync', true ); body? body.appendChild(coreCall) : head.appendChild(coreCall); })(document, document.head, document.body); </script>
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Laser_Peripheral_Iridotomy rootpage-Laser_Peripheral_Iridotomy layout-standard skin-chameleon action-view">
	<div class="flex-fill container">
		<div class="row">
			<div class="flex-grow-0 col-12 col-cmln-6 d-flex flex-column flex-md-row w-md-100 justify-content-start align-items-center col">
					<div class="float-left mr-3 mb-2"><a href="//aao.org"><img id="aao-logo" src="/w/extensions/EyeWiki/skins/chameleon/AAO_Logo.png"></a></div>
                		
				<!-- logo and main page link -->
				<div id="p-logo" class="p-logo" role="banner">
					<a href="/Main_Page" title="Visit the main page"><img src="/w/extensions/EyeWiki/skins/chameleon/EyeWiki_Logo.png" alt="EyeWiki"/></a>
				</div>
			</div>
			<div class="ml-auto col-12 col-cmln col">
				<div class="row">
					<div class="col">
						<!-- personal tools -->
						<div class="p-personal pull-right" id="p-personal" >
							<ul class="p-personal-tools" >
								<li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Laser+Peripheral+Iridotomy" title="You are encouraged to create an account and log in; however, it is not mandatory" class="pt-createaccount">Create account</a></li>
								<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Laser+Peripheral+Iridotomy" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o" class="pt-login">Log in</a></li>
							</ul>
						</div>

					</div>
				</div>
				<div class="row">
					<div class="col">
						<!-- search form -->
						<div  id="p-search" class="p-search pull-right" role="search"  >
							<form  id="searchform" class="mw-search" action="/w/index.php" >
								<input type="hidden" name="title" value=" Special:Search" />
								<div class="input-group">
									<input name="search" placeholder="Search EyeWiki" title="Search EyeWiki [f]" accesskey="f" id="searchInput" class="form-control"/>
									<div class="input-group-append">
										<button value="Go" id="searchGoButton" name="go" type="submit" class="search-btn searchGoButton" aria-label="Go to page" title="Go to a page with this exact name if it exists"></button>
									</div>
								</div>
							</form>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar collapsible mb-3 mt-2 p-1 mt-cmln-0" role="navigation" id="mw-navigation">
					<button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#hbpzywijut"></button>
					<div class="collapse navbar-collapse hbpzywijut" id="hbpzywijut">
						<div class="navbar-nav"><div class="nav-item"><a class="nav-link fas fa-home"  href="/Main_Page">Main Page</a></div><div class="nav-item"><a class="nav-link fas fa-book"  href="/Category:Articles">Articles</a></div><div class="nav-item"><a class="nav-link fas fa-play"  href="/Help:Getting_Started">Getting Started</a></div><div class="nav-item"><a class="nav-link fas fa-question"  href="/Help:Contents">Help</a></div><div class="nav-item"><a class="nav-link fas fa-backward"  href="/Special:RecentChanges">Recent changes</a></div><div class="nav-item"><a class="nav-link fas fa-door-open"  href="#">My Portal</a></div>
						</div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- Content navigation -->
				<div class="mb-3 pagetools p-contentnavigation" id="p-contentnavigation">
					<!-- namespaces -->
					<div id="p-namespaces" class="p-namespaces">
						<div class="tab-group">
							<div id="ca-nstab-main" class="selected"><a href="/Laser_Peripheral_Iridotomy" title="View the content page [c]" accesskey="c" class="selected ca-nstab-main">Page</a></div>
							<div id="ca-talk" class="new"><a href="/w/index.php?title=Talk:Laser_Peripheral_Iridotomy&amp;action=edit&amp;redlink=1" rel="discussion" title="Discussion about the content page (page does not exist) [t]" accesskey="t" class="new ca-talk">Discussion</a></div>
						</div>
					</div>
					<!-- views -->
					<div id="p-views" class="p-views">
						<div class="tab-group">
							<div id="ca-formedit"><a href="/w/index.php?title=Laser_Peripheral_Iridotomy&amp;action=formedit" title="Edit this page with a form [&amp;]" accesskey="&amp;" class="ca-formedit">View form</a></div>
							<div id="ca-viewsource"><a href="/w/index.php?title=Laser_Peripheral_Iridotomy&amp;action=edit" title="This page is protected.&#10;You can view its source [e]" accesskey="e" class="ca-viewsource">View source</a></div>
							<div id="ca-history"><a href="/w/index.php?title=Laser_Peripheral_Iridotomy&amp;action=history" title="Past revisions of this page [h]" accesskey="h" class="ca-history">History</a></div>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">

			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- start the content area -->
				<div id="content" class="mw-body content"><a id="top" class="top"></a>
					<div id="mw-indicators" class="mw-indicators">
					<div id="mw-indicator-smw-entity-examiner" class="mw-indicator mw-indicator-smw-entity-examiner"><div class="smw-entity-examiner smw-indicator-vertical-bar-loader" data-subject="Laser_Peripheral_Iridotomy#0##" data-dir="ltr" data-uselang="" title="Running an examiner in the background"></div></div>
				</div>
						<div class="contentHeader">
						<!-- title of the page -->
						<h1 id="firstHeading" class="firstHeading">Laser Peripheral Iridotomy</h1>
						<!-- tagline; usually goes something like "From WikiName" primary purpose of this seems to be for printing to identify the source of the content -->
						<div id="siteSub" class="siteSub">From EyeWiki</div><div id="jump-to-nav" class="mw-jump jump-to-nav">Jump to:<a href="#mw-navigation">navigation</a>, <a href="#p-search">search</a></div>
					</div>
					<div id="bodyContent" class="bodyContent">
						<!-- body text -->

						<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="mw-parser-output"><div id="article-header" data-description2-ignore=""><div id="contest" style="margin-bottom: 6px;">
</div>
<div class="infobox contributors">
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header"><a href="/Property:Authors" title="Property:Authors">Article initiated by</a>:
</div>
<div class="info-section-body"><a href="/User:Ana.Miguel" title="User:Ana.Miguel">Ana IM Miguel</a>,&#8201;<a href="/User:Andre.Silva" title="User:Andre.Silva">André Borges Silva</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">All authors and contributors:
</div>
<div class="info-section-body"> <a href="/User:Ana.Miguel" title="User:Ana.Miguel">Ana IM Miguel</a>,&#160;<a href="/w/index.php?title=User:Sara_HM_Marques&amp;action=formedit&amp;redlink=1" class="new" title="User:Sara HM Marques (page does not exist)">Sara HM Marques</a>,&#160;<a href="/w/index.php?title=User:M%C3%A1rio_Cruz&amp;action=formedit&amp;redlink=1" class="new" title="User:Mário Cruz (page does not exist)">Mário Cruz</a>,&#160;<a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a>,&#160;<a href="/User:Andre.Silva" title="User:Andre.Silva">André Borges Silva</a>,&#160;<a href="/User:Jonathan.Tsui" title="User:Jonathan.Tsui">Jonathan C. Tsui, MD</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Assigned editor:
</div>
<div class="info-section-body"> <a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a></div>
</div><div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Review:
</div>
<div class="info-section-body">Assigned status <b>Up to Date</b>
</div>
</div>&#160;by <a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a> on December 25, 2022.
</div>
<div style="display:none;">
<table cellspacing="5">

<tbody><tr>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Laser_Peripheral_Iridotomy&amp;action=formedit">add</a></small>
</td></tr>
<tr>
<th align="right"><b><a href="/Property:Contributing_Editors" title="Property:Contributing Editors">Contributing Editors</a>:</b>
</th>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Laser_Peripheral_Iridotomy&amp;action=formedit">add</a></small>
</td></tr>
</tbody></table></div>
<div style="display:none;">
<p><br />
</p>
</div>
<div id="local-videos">
</div>
</div>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Introduction"><span class="tocnumber">1</span> <span class="toctext">Introduction</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Indications"><span class="tocnumber">2</span> <span class="toctext">Indications</span></a>
<ul>
<li class="toclevel-2 tocsection-3"><a href="#1._Acute_Primary_Angle_Closure_.28APAC.29"><span class="tocnumber">2.1</span> <span class="toctext">1.  Acute Primary Angle Closure (APAC)</span></a></li>
<li class="toclevel-2 tocsection-4"><a href="#2._Contralateral_Eye_in_Acute_Primary_Angle_Closure"><span class="tocnumber">2.2</span> <span class="toctext">2. Contralateral Eye in Acute Primary Angle Closure</span></a></li>
<li class="toclevel-2 tocsection-5"><a href="#3._Primary-Angle_Closure_suspect_.28PACS.29.2C_.E2.80.9Cnarrow.E2.80.9D_or_.E2.80.9Coccludable.E2.80.9D_angle"><span class="tocnumber">2.3</span> <span class="toctext">3. Primary-Angle Closure suspect (PACS), “narrow” or “occludable” angle</span></a></li>
<li class="toclevel-2 tocsection-6"><a href="#4._Primary_Angle_Closure_.28PAC.29_and_Primary_Angle-Closure_Glaucoma_.28PACG.29"><span class="tocnumber">2.4</span> <span class="toctext">4. Primary Angle Closure (PAC) and Primary Angle-Closure Glaucoma (PACG)</span></a></li>
<li class="toclevel-2 tocsection-7"><a href="#5._Secondary_Angle-Closure_Mechanisms"><span class="tocnumber">2.5</span> <span class="toctext">5. Secondary Angle-Closure Mechanisms</span></a></li>
<li class="toclevel-2 tocsection-8"><a href="#6._Other_Indications"><span class="tocnumber">2.6</span> <span class="toctext">6. Other Indications</span></a>
<ul>
<li class="toclevel-3 tocsection-9"><a href="#1._Pigmentary_Dispersion_Syndrome_.28PDS.29.2C_Pigmentary_Ocular_Hypertension_.28POH.29_and_Pigmentary_Glaucoma_.28PG.29"><span class="tocnumber">2.6.1</span> <span class="toctext">1. Pigmentary Dispersion Syndrome (PDS), Pigmentary Ocular Hypertension (POH) and Pigmentary Glaucoma (PG)</span></a></li>
<li class="toclevel-3 tocsection-10"><a href="#2._Plateau_Iris_Configuration_and_Plateau_Iris_Syndrome"><span class="tocnumber">2.6.2</span> <span class="toctext">2. Plateau Iris Configuration and Plateau Iris Syndrome</span></a></li>
<li class="toclevel-3 tocsection-11"><a href="#3._Aqueous_Misdirection.2C_Cilio-lenticular_block.2C_Ciliary_Block_or_Malignant_Glaucoma"><span class="tocnumber">2.6.3</span> <span class="toctext">3. Aqueous Misdirection, Cilio-lenticular block, Ciliary Block or Malignant Glaucoma</span></a></li>
<li class="toclevel-3 tocsection-12"><a href="#4._Congenital_anomalies_that_can_be_associated_with_secondary_glaucoma"><span class="tocnumber">2.6.4</span> <span class="toctext">4. Congenital anomalies that can be associated with secondary glaucoma</span></a></li>
<li class="toclevel-3 tocsection-13"><a href="#5._Systemic_drugs_with_effects_on_the_iridocorneal_angle"><span class="tocnumber">2.6.5</span> <span class="toctext">5. Systemic drugs with effects on the iridocorneal angle</span></a></li>
</ul>
</li>
</ul>
</li>
<li class="toclevel-1 tocsection-14"><a href="#Contraindications"><span class="tocnumber">3</span> <span class="toctext">Contraindications</span></a></li>
<li class="toclevel-1 tocsection-15"><a href="#Preoperative_Management"><span class="tocnumber">4</span> <span class="toctext">Preoperative Management</span></a></li>
<li class="toclevel-1 tocsection-16"><a href="#Types_of_Lasers_for_LPI"><span class="tocnumber">5</span> <span class="toctext">Types of Lasers for LPI</span></a>
<ul>
<li class="toclevel-2 tocsection-17"><a href="#Argon.2FNd:YAG-KTP_532_nm_or_solid-state_Laser"><span class="tocnumber">5.1</span> <span class="toctext">Argon/Nd:YAG-KTP 532 nm or solid-state Laser</span></a></li>
<li class="toclevel-2 tocsection-18"><a href="#Nd:YAG_laser_iridotomy"><span class="tocnumber">5.2</span> <span class="toctext">Nd:YAG laser iridotomy</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-19"><a href="#Complications"><span class="tocnumber">6</span> <span class="toctext">Complications</span></a>
<ul>
<li class="toclevel-2 tocsection-20"><a href="#1._Transient_Increase_in_IOP"><span class="tocnumber">6.1</span> <span class="toctext">1. Transient Increase in IOP</span></a></li>
<li class="toclevel-2 tocsection-21"><a href="#2._Anterior_Chamber_Bleeding_.28Hyphema.29"><span class="tocnumber">6.2</span> <span class="toctext">2. Anterior Chamber Bleeding (Hyphema)</span></a></li>
<li class="toclevel-2 tocsection-22"><a href="#3._Visual_Dysphotopsias"><span class="tocnumber">6.3</span> <span class="toctext">3. Visual Dysphotopsias</span></a></li>
<li class="toclevel-2 tocsection-23"><a href="#4._Cataract_Progression"><span class="tocnumber">6.4</span> <span class="toctext">4. Cataract Progression</span></a></li>
<li class="toclevel-2 tocsection-24"><a href="#5._Iridotomy_closure_and_necessity_for_repeat_LPI"><span class="tocnumber">6.5</span> <span class="toctext">5. Iridotomy closure and necessity for repeat LPI</span></a></li>
<li class="toclevel-2 tocsection-25"><a href="#6._Aqueous_misdirection_syndrome"><span class="tocnumber">6.6</span> <span class="toctext">6. Aqueous misdirection syndrome</span></a></li>
<li class="toclevel-2 tocsection-26"><a href="#Other_complications"><span class="tocnumber">6.7</span> <span class="toctext">Other complications</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-27"><a href="#Outcomes"><span class="tocnumber">7</span> <span class="toctext">Outcomes</span></a>
<ul>
<li class="toclevel-2 tocsection-28"><a href="#1._IOP_control"><span class="tocnumber">7.1</span> <span class="toctext">1. IOP control</span></a></li>
<li class="toclevel-2 tocsection-29"><a href="#2._Anatomical_improvement"><span class="tocnumber">7.2</span> <span class="toctext">2. Anatomical improvement</span></a></li>
<li class="toclevel-2 tocsection-30"><a href="#3._Prevention_of_AAC_crisis"><span class="tocnumber">7.3</span> <span class="toctext">3. Prevention of AAC crisis</span></a></li>
<li class="toclevel-2 tocsection-31"><a href="#4._Disease_Progression"><span class="tocnumber">7.4</span> <span class="toctext">4. Disease Progression</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-32"><a href="#Summary"><span class="tocnumber">8</span> <span class="toctext">Summary</span></a></li>
<li class="toclevel-1 tocsection-33"><a href="#References"><span class="tocnumber">9</span> <span class="toctext">References</span></a></li>
</ul>
</div>

<h2><span class="mw-headline" id="Introduction">Introduction</span></h2>
<div class="thumb tright"><div class="thumbinner" style="width:402px;"><a href="/File:Fiche_no_256021_17mai2019_CUDELOU_ANDRE_1.png" class="image"><img alt="" src="/w/images/1/thumb/d/de/Fiche_no_256021_17mai2019_CUDELOU_ANDRE_1.png/400px-Fiche_no_256021_17mai2019_CUDELOU_ANDRE_1.png" decoding="async" width="400" height="320" class="thumbimage" srcset="/w/images/1/thumb/d/de/Fiche_no_256021_17mai2019_CUDELOU_ANDRE_1.png/600px-Fiche_no_256021_17mai2019_CUDELOU_ANDRE_1.png 1.5x, /w/images/1/d/de/Fiche_no_256021_17mai2019_CUDELOU_ANDRE_1.png 2x" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/File:Fiche_no_256021_17mai2019_CUDELOU_ANDRE_1.png" class="internal" title="Enlarge"></a></div>Slit lamp photo of a superior iridotomy at 10 o'clock.   <i>Credits: Professor Ana IM Miguel, Polyclinique de la Baie, France.</i></div></div></div>
<p>Laser peripheral iridotomy (also described as ‘laser iridotomy’ or simply termed 'iridotomy') is a medical procedure which uses a laser device to create a hole in the iris, thereby allowing aqueous humor to traverse directly from the posterior to the anterior chamber and, consequently, relieve a pupillary block.<sup id="cite_ref-bMJ1_1-0" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup><sup id="cite_ref-prum2_2-0" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup><sup id="cite_ref-lam3_3-0" class="reference"><a href="#cite_note-lam3-3">&#91;3&#93;</a></sup> It is commonly used to treat a wide range of clinical conditions, encompassing primary angle‐closure glaucoma, primary angle closure (narrow angles and no signs of glaucomatous optic neuropathy), patients who are primary angle‐closure suspects (patients with reversible obstruction) and even eyes with secondary causes of iridocorneal angle-closure.<sup id="cite_ref-bMJ1_1-1" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup> 
</p><p>The first report of an effective surgical treatment for glaucoma was made in 1857 by the German ophthalmologist Albrecht von Graefe, who described the execution of a broad-sector surgical iridectomy through a corneal wound.<sup id="cite_ref-gr.C3.A4fe4_4-0" class="reference"><a href="#cite_note-gr.C3.A4fe4-4">&#91;4&#93;</a></sup>
</p><p>However, since the emergence of laser technology in the field of ophthalmology, laser peripheral iridotomy (LPI) has largely surpassed the former technique. In the mid-1970’s, argon laser became the first to be routinely used to perform a non-invasive iridotomy.<sup id="cite_ref-cruz5_5-0" class="reference"><a href="#cite_note-cruz5-5">&#91;5&#93;</a></sup><sup id="cite_ref-khuri6_6-0" class="reference"><a href="#cite_note-khuri6-6">&#91;6&#93;</a></sup><sup id="cite_ref-palanker7_7-0" class="reference"><a href="#cite_note-palanker7-7">&#91;7&#93;</a></sup> Although it is well absorbed by iris pigment, argon laser (and Nd:YAG-KTP laser, which is often referred to as "argon laser") iridotomy alone was associated with some complications and relatively high failure and subsequent closure rates.<sup id="cite_ref-cruz5_5-1" class="reference"><a href="#cite_note-cruz5-5">&#91;5&#93;</a></sup><sup id="cite_ref-quigley8_8-0" class="reference"><a href="#cite_note-quigley8-8">&#91;8&#93;</a></sup><sup id="cite_ref-robin9_9-0" class="reference"><a href="#cite_note-robin9-9">&#91;9&#93;</a></sup> Q-switched Nd:YAG laser (YAG laser 1064 nm) devices surfaced in the 1980’s and demonstrated to be effective in light-coloured irides because its mechanism of action was independent of the melanin content of the iris. Furthermore, it required considerably less total energy than pure argon/Nd:YAG-KTP 532 nm laser iridotomy, achieved a superior rate of single treatment success with lower risk of subsequent closure and was less likely to cause damage to the cornea, lens and retina.<sup id="cite_ref-lam3_3-1" class="reference"><a href="#cite_note-lam3-3">&#91;3&#93;</a></sup><sup id="cite_ref-cruz5_5-2" class="reference"><a href="#cite_note-cruz5-5">&#91;5&#93;</a></sup><sup id="cite_ref-berger10_10-0" class="reference"><a href="#cite_note-berger10-10">&#91;10&#93;</a></sup><sup id="cite_ref-vijaya11_11-0" class="reference"><a href="#cite_note-vijaya11-11">&#91;11&#93;</a></sup><sup id="cite_ref-kumar12_12-0" class="reference"><a href="#cite_note-kumar12-12">&#91;12&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Indications">Indications</span></h2>
<p>Laser peripheral iridotomy (LPI) is indicated to prevent or overcome a suspected relative pupillary block by creating an alternative pathway for aqueous flow. Mainly used for patients in the primary angle closure spectrum, it can also be useful in secondary angle closure glaucoma and in the management of other types of glaucoma with associated pupillary block. The iridocorneal angle should be, in all cases, carefully examined after LPI to rule out other mechanisms of a closed angle requiring treatment.<sup id="cite_ref-international13_13-0" class="reference"><a href="#cite_note-international13-13">&#91;13&#93;</a></sup>
The indications for LPI are summarized in table 1.
</p><p><span><a href="/File:Table_1_LPI.png" class="image"><img alt="Table 1 LPI.png" src="/w/images/1/thumb/a/a8/Table_1_LPI.png/500px-Table_1_LPI.png" decoding="async" width="500" height="281" srcset="/w/images/1/a/a8/Table_1_LPI.png 1.5x" /></a></span><br />  
</p>
<h3><span id="1._Acute_Primary_Angle_Closure_(APAC)"></span><span class="mw-headline" id="1._Acute_Primary_Angle_Closure_.28APAC.29">1.  Acute Primary Angle Closure (APAC)</span></h3>
<p>The benefit of LPI is well established to treat and prevent an acute angle closure (AAC) crisis. The technique is usually performed soon after the diagnosis is made in order to prevent irreversible vision loss and prevent a recurrent AAC episode. It is essential to perform LPI in the fellow eye when indicated.<sup id="cite_ref-prum2_2-1" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup><sup id="cite_ref-lam3_3-2" class="reference"><a href="#cite_note-lam3-3">&#91;3&#93;</a></sup>
Before performing an LPI, however, patients experiencing APAC should receive aqueous suppressants to lower the IOP, relieve symptoms, improve cooperation and visualization of the ocular media in order to safely and effectively apply the laser beam.<sup id="cite_ref-prum2_2-2" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup><sup id="cite_ref-lam3_3-3" class="reference"><a href="#cite_note-lam3-3">&#91;3&#93;</a></sup><sup id="cite_ref-cruz5_5-3" class="reference"><a href="#cite_note-cruz5-5">&#91;5&#93;</a></sup>
In conclusion, LPI associated with medical treatment is the preferred definitive treatment of acute angle-closure glaucoma with a pupillary block mechanism.<sup id="cite_ref-bMJ1_1-2" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="2._Contralateral_Eye_in_Acute_Primary_Angle_Closure">2. Contralateral Eye in Acute Primary Angle Closure</span></h3>
<p>The fellow eye of a patient with AAC crisis should be evaluated because it is at high risk for a similar event and can occur within days of the first episode.<sup id="cite_ref-prum2_2-3" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup> LPI is indicated in gonioscopically-proven occludable angles after an AAC episode as 50% of patients will suffer a second attack in the fellow eye over a 5-year period.<sup id="cite_ref-bMJ1_1-3" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup><sup id="cite_ref-prum2_2-4" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup><sup id="cite_ref-lowe14_14-0" class="reference"><a href="#cite_note-lowe14-14">&#91;14&#93;</a></sup><sup id="cite_ref-bain15_15-0" class="reference"><a href="#cite_note-bain15-15">&#91;15&#93;</a></sup>The risk is significantly reduced if an iridotomy or iridectomy is performed in this eye.<sup id="cite_ref-prum2_2-5" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup><sup id="cite_ref-ang16_16-0" class="reference"><a href="#cite_note-ang16-16">&#91;16&#93;</a></sup>
</p>
<h3><span id="3._Primary-Angle_Closure_suspect_(PACS),_“narrow”_or_“occludable”_angle"></span><span class="mw-headline" id="3._Primary-Angle_Closure_suspect_.28PACS.29.2C_.E2.80.9Cnarrow.E2.80.9D_or_.E2.80.9Coccludable.E2.80.9D_angle">3. Primary-Angle Closure suspect (PACS), “narrow” or “occludable” angle</span></h3>
<p>These eyes feature at least 2 quadrants of iridotrabecular contact (ITC) but normal IOP, no peripheral anterior synechiae (PAS) and no evidence of glaucomatous optic neuropathy or visual field defects. Observational studies suggest that the majority of these eyes will not develop either PAC or PACG.<sup id="cite_ref-prum2_2-6" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup><sup id="cite_ref-wilensky17_17-0" class="reference"><a href="#cite_note-wilensky17-17">&#91;17&#93;</a></sup>
All cases of PACS must be assessed individually. In general, the treatment complications are to be balanced against the perceived risk of angle-closure.<sup id="cite_ref-bMJ1_1-4" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup><sup id="cite_ref-prum2_2-7" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup><sup id="cite_ref-cruz5_5-4" class="reference"><a href="#cite_note-cruz5-5">&#91;5&#93;</a></sup>The ZAP trial<sup id="cite_ref-jiang18_18-0" class="reference"><a href="#cite_note-jiang18-18">&#91;18&#93;</a></sup> demonstrated a small, but significant, prophylactic effect of LPI in these cases, however, the widespread use of prophylactic LPI for PACS or “occludable angles” is not recommended. Therefore, some authors defend that following such patients without treatment is a safe option.<sup id="cite_ref-prum2_2-8" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup><sup id="cite_ref-weinreb19_19-0" class="reference"><a href="#cite_note-weinreb19-19">&#91;19&#93;</a></sup>
</p>
<h3><span id="4._Primary_Angle_Closure_(PAC)_and_Primary_Angle-Closure_Glaucoma_(PACG)"></span><span class="mw-headline" id="4._Primary_Angle_Closure_.28PAC.29_and_Primary_Angle-Closure_Glaucoma_.28PACG.29">4. Primary Angle Closure (PAC) and Primary Angle-Closure Glaucoma (PACG)</span></h3>
<p>Iridotomy is strongly recommended in eyes with PAC or PACG.<sup id="cite_ref-bMJ1_1-5" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup><sup id="cite_ref-prum2_2-9" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup><sup id="cite_ref-weinreb20_20-0" class="reference"><a href="#cite_note-weinreb20-20">&#91;20&#93;</a></sup> PAC patients may have elevated IOP from chronic compromise of aqueous outflow. Chronic angle-closure glaucoma features permanent synechial closure of any extent as confirmed by indentation gonioscopy.<sup id="cite_ref-bMJ1_1-6" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup>
Medical treatment alone is contraindicated as all patients require relief of pupil block by iridotomy, iridectomy or lens extraction. If the peripheral anterior synechiae occupy less than 50% of the circumference, iridectomy or iridotomy may suffice. Since complications of laser iridotomy are uncommon, its use as the initial procedure is justified in practically every case, as soon as the corneal transparency allows the LPI to be performed. If IOP remains uncontrolled after LPI, a filtering surgery should be considered as the next step.<sup id="cite_ref-bMJ1_1-7" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup>
However, In asymptomatic (“chronic”) angle-closure, a high presenting pressure (&gt;35 mmHg), more than 6-clock hours of peripheral anterior synechiae and/or established glaucomatous optic neuropathy are signs that the angle-closure will not respond fully to an LPI, and that surgical treatment may be needed to reach the IOP goal.<sup id="cite_ref-bMJ1_1-8" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="5._Secondary_Angle-Closure_Mechanisms">5. Secondary Angle-Closure Mechanisms</span></h3>
<p>Uveitis is a common cause of secondary pupillary block and laser iridotomy may be required to prevent recurrence of pupillary block. Pupillary block can also develop slowly with a senile cataract or rapidly with dislocated or subluxated lenses, or with swollen post-trauma lenses. Iridotomy may not be curative, but helps by relieving pupillary block component, allowing for safer lensectomy. Pupillary block can occur in pseudophakic eyes, more often with anterior chamber lenses if an iridectomy is absent or occluded.<sup id="cite_ref-bMJ1_1-9" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup><sup id="cite_ref-lam3_3-4" class="reference"><a href="#cite_note-lam3-3">&#91;3&#93;</a></sup><sup id="cite_ref-cruz5_5-5" class="reference"><a href="#cite_note-cruz5-5">&#91;5&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="6._Other_Indications">6. Other Indications</span></h3>
<h4><span id="1._Pigmentary_Dispersion_Syndrome_(PDS),_Pigmentary_Ocular_Hypertension_(POH)_and_Pigmentary_Glaucoma_(PG)"></span><span class="mw-headline" id="1._Pigmentary_Dispersion_Syndrome_.28PDS.29.2C_Pigmentary_Ocular_Hypertension_.28POH.29_and_Pigmentary_Glaucoma_.28PG.29">1. Pigmentary Dispersion Syndrome (PDS), Pigmentary Ocular Hypertension (POH) and Pigmentary Glaucoma (PG)</span></h4>
<p>In PDS, the principle supporting LPI is to equalize the pressure between the anterior and posterior chamber so as to reduce the posterior concavity of the iris. This would allow for reduced friction between the iris and zonular fibers and reduce or eliminate pigment dispersion.<sup id="cite_ref-bMJ1_1-10" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup><sup id="cite_ref-prum2_2-10" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup><sup id="cite_ref-michelessi21_21-0" class="reference"><a href="#cite_note-michelessi21-21">&#91;21&#93;</a></sup><sup id="cite_ref-buffault22_22-0" class="reference"><a href="#cite_note-buffault22-22">&#91;22&#93;</a></sup>
ND:YAG LPI has been proposed as a means for eliminating a reverse pupillary block, although the benefit from an LPI in patients with PDS, POH and PG is not yet established. However, LPI has demonstrated to decrease the biomechanical factor of iris-zonule contact, which may prove to be beneficial to patients before the onset of trabecular dysfunction. There is insufficient evidence of high quality on the effectiveness of peripheral iridotomy for pigmentary glaucoma or pigment dispersion syndrome and, therefore, the long-term effects on visual function and other patient-important outcomes have not been established. In pigmentary glaucoma, this procedure is usually not recommended, since there is already an optic neuropathy which can progress with IOP spikes after LPI.<sup id="cite_ref-michelessi21_21-1" class="reference"><a href="#cite_note-michelessi21-21">&#91;21&#93;</a></sup><sup id="cite_ref-buffault22_22-1" class="reference"><a href="#cite_note-buffault22-22">&#91;22&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="2._Plateau_Iris_Configuration_and_Plateau_Iris_Syndrome">2. Plateau Iris Configuration and Plateau Iris Syndrome</span></h4>
<p>Plateau Iris configuration refers to a specific condition in which eyes to have ITC after iridotomy, with close apposition of the peripheral iris to the angle on gonioscopy and a deep central anterior chamber.<sup id="cite_ref-bMJ1_1-11" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup><sup id="cite_ref-prum2_2-11" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup> On pupil dilation, these eyes do not experience a significant increase of IOP as opposed to eyes with Plateau Iris Syndrome, which experience an IOP spike in this scenario  and may require more extensive treatments. About one third of eyes with PAC treated with LPI have an angle that retains significant ITC.<sup id="cite_ref-prum2_2-12" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup><sup id="cite_ref-kumar24_23-0" class="reference"><a href="#cite_note-kumar24-23">&#91;23&#93;</a></sup> LPI should be performed in every eye suspected of having a Plateau Iris configuration, since it eliminates any pupillary block component.<sup id="cite_ref-bMJ1_1-12" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup><sup id="cite_ref-prum2_2-13" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup> 
These eyes present a thicker iris and an anteversion of the ciliary body and these anatomical factors predict failure of a laser iridotomy to open an appositionally closed angle.<sup id="cite_ref-prum2_2-14" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup><sup id="cite_ref-cruz5_5-6" class="reference"><a href="#cite_note-cruz5-5">&#91;5&#93;</a></sup>
The long-term risk of PACG in eyes with Plateau Iris configuration does not appear to be higher than in eyes whose angles widen more after LPI.<sup id="cite_ref-prum2_2-15" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup>
</p>
<h4><span id="3._Aqueous_Misdirection,_Cilio-lenticular_block,_Ciliary_Block_or_Malignant_Glaucoma"></span><span class="mw-headline" id="3._Aqueous_Misdirection.2C_Cilio-lenticular_block.2C_Ciliary_Block_or_Malignant_Glaucoma">3. Aqueous Misdirection, Cilio-lenticular block, Ciliary Block or Malignant Glaucoma</span></h4>
<p>Aqueous misdirection is a challenging form of secondary angle closure that presents with elevated intraocular pressure (IOP) and shallowing of the central and peripheral anterior chamber caused by anterior rotation of the iris and ciliary body, occurring classically in the post-operative period. Since this clinical entity is a diagnosis of exclusion, LPI is important since it eliminates the possibility of a pupillary block mechanism in ciliary block glaucoma.<sup id="cite_ref-bMJ1_1-13" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="4._Congenital_anomalies_that_can_be_associated_with_secondary_glaucoma">4. Congenital anomalies that can be associated with secondary glaucoma</span></h4>
<p>Familial iris hypoplasia, anomalous superficial iris vessels, aniridia, Sturge-Weber syndrome, neurofibromatosis, Marfan’s syndrome, Pierre Robin syndrome, homocystinuria, goniodysgenesis, Lowe’s syndrome, microcornea, microspherophakia, rubella, broad thumb syndrome, persistent hyperplastic primary vitreous. Laser iridotomy and surgical iridectomy are not effective.<sup id="cite_ref-bMJ1_1-14" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="5._Systemic_drugs_with_effects_on_the_iridocorneal_angle">5. Systemic drugs with effects on the iridocorneal angle</span></h4>
<p>A wide range of systemic drugs (e.g. topiramate, methylphenidate, selective serotonin re-uptake inhibitors, tricyclic antidepressants) have been implicated in case reports with angle-closure, however, these eyes pose added difficulties in the decision-making process since the pre-treatment gonioscopy findings alone are not enough to rule out such risk. It is sensible to repeat the gonioscopy in eyes with narrow angles whenever these drugs are initiated. The role of prophylactic LPI in this patient population should weighed against the risk of angle-closure or of withdrawal of these drugs.<sup id="cite_ref-bMJ1_1-15" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup><sup id="cite_ref-prum2_2-16" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Contraindications">Contraindications</span></h2>
<p>The following contraindications should be managed prior to performing an LPI.<sup id="cite_ref-prum2_2-17" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup><sup id="cite_ref-lam3_3-5" class="reference"><a href="#cite_note-lam3-3">&#91;3&#93;</a></sup><sup id="cite_ref-cruz5_5-7" class="reference"><a href="#cite_note-cruz5-5">&#91;5&#93;</a></sup>
</p>
<ul><li>Ocular media opacities (e.g. corneal edema, anterior chamber inflammation)</li>
<li>High risk eyes (e.g. very shallow or flat anterior chambers, uveitis)</li>
<li>Uncooperative patients.</li></ul>
<p><br />
</p>
<h2><span class="mw-headline" id="Preoperative_Management">Preoperative Management</span></h2>
<p>The following recommendations should be followed in order to safely and effectively perform an LPI:<sup id="cite_ref-bMJ1_1-16" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup><sup id="cite_ref-prum2_2-18" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup><sup id="cite_ref-cruz5_5-8" class="reference"><a href="#cite_note-cruz5-5">&#91;5&#93;</a></sup><sup id="cite_ref-weinreb20_20-1" class="reference"><a href="#cite_note-weinreb20-20">&#91;20&#93;</a></sup>
</p>
<ol><li>Apply pilocarpine 2%-4% to cause miosis, reduce iris thickness and facilitate perforation.</li>
<li>In the presence of corneal edema, use topical glycerin 10% if available, systemic acetazolamide, intravenous mannitol or oral hyperosmotic agents.</li>
<li>IOP-lowering drugs: to prevent IOP spikes after the procedure use topical alpha-2 agonist (brimonidine or apraclonidine) 1 hour prior to the procedure and immediately afterwards. In the setting of AAC, IOP should be controlled beforehand with medical treatment.</li>
<li>Apply topical anaesthesia (e.g. oxybuprocaine).<div class="thumb tright"><div class="thumbinner" style="width:302px;"><a href="/File:Nasal_Iridotomy.png" class="image"><img alt="" src="/w/images/1/thumb/0/03/Nasal_Iridotomy.png/300px-Nasal_Iridotomy.png" decoding="async" width="300" height="240" class="thumbimage" srcset="/w/images/1/thumb/0/03/Nasal_Iridotomy.png/450px-Nasal_Iridotomy.png 1.5x, /w/images/1/thumb/0/03/Nasal_Iridotomy.png/600px-Nasal_Iridotomy.png 2x" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/File:Nasal_Iridotomy.png" class="internal" title="Enlarge"></a></div>Slit lamp photo of a nasal iridotomy at 9 o' clock visualized by transillumination.<i>Credits: Professor Ana IM Miguel, Polyclinique de la Baie, France.</i></div></div></div></li>
<li>Apply iridotomy lens (e.g.Abraham (+66 diopters), Wise (+103 diopters) or CGI©LASAG CH lens) to the eye with coupling gel. The use of the lens keeps the eyelids open, minimizes eye movement, provides magnification and improves visualization, reducing the risk of corneal burns and simultaneously increases the power density by concentrating the laser energy.</li>
<li>Focus: Set defocus to zero, focus first on the iris surface and then offset the YAG beam so that it converges slightly posteriorly in the stroma. A bubble of plasma travels towards the surgeon so it is safer to have the focal point within the iris stroma.</li>
<li>Position of iridotomy: The hole should be created in the iris periphery, aiming for an iris crypt or area of iris thinning, at a site in the superior quadrants between 11 and 1 o’clock, which allows the lesion to be covered by the upper eyelid, avoiding the 12 o'clock position as air bubbles may occlude the iridotomy. Avoid iris vessels. If silicone oil (except high MW silicone) or other tamponading fluids or gases present, perform an inferior LPI.</li>
<li>Parameters: Consult tables 2 and 3.</li>
<li>Endpoint: A small (150 to 200 micron), peripheral and completely patent is the ideal result. Whole thickness perforation of the iris is assumed when pigment, mixed with aqueous, flows from the posterior into the anterior chamber. Once a full thickness hole has been made, it should be enlarged horizontally to achieve an adequate size. Iridotomy size should be sufficient for patency in spite of iris oedema, pigment epithelial proliferation and pupil dilation. Transillumination through the iridotomy is not a reliable indicator of patency<div class="thumb tright"><div class="thumbinner" style="width:302px;"><a href="/File:Inferior_Iridotomy.png" class="image"><img alt="" src="/w/images/1/thumb/3/3e/Inferior_Iridotomy.png/300px-Inferior_Iridotomy.png" decoding="async" width="300" height="240" class="thumbimage" srcset="/w/images/1/thumb/3/3e/Inferior_Iridotomy.png/450px-Inferior_Iridotomy.png 1.5x, /w/images/1/thumb/3/3e/Inferior_Iridotomy.png/600px-Inferior_Iridotomy.png 2x" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/File:Inferior_Iridotomy.png" class="internal" title="Enlarge"></a></div>Slit lamp photo of an inferior iridotomy in a vitrectomized eye.<i>Credits: Professor Ana IM Miguel, Polyclinique de la Baie, France.</i></div></div></div></li>
<li>Post-operative medication: Prescribe a topical corticosteroid 3 to 4 times a day for 4-7 days as well as a IOP-lowering drug.</li>
<li>Evaluate IOP in 30 minutes to 2 hours following LPI and anterior chamber depth one week later to confirm opening of the AC angle. If the patency is uncertain check with gonioscopy, reconsider the mechanism, perform ultrasound biomicroscopy (UBM) / anterior segment-optical coherence tomography (AS-OCT) if available and/or repeat the iridotomy.</li></ol>
<p><br />
</p>
<h2><span class="mw-headline" id="Types_of_Lasers_for_LPI">Types of Lasers for LPI</span></h2>
<p>Iridotomy can be accomplished using the photodisruptive Q-switched Nd:YAG laser (Nd:YAG) or the photo-thermal Nd:YAG-KTP 532 nm (which is still often called Argon laser) and solid-state lasers. 
The two laser types may also be used in sequential combination. Laser parameters should be individualized to each patient and adjusted appropriately during the procedure. Independently of the device used, some authors aim for an iridotomy of at least 200 microns in size and ideally 500 micron in diameter.<sup id="cite_ref-lam3_3-6" class="reference"><a href="#cite_note-lam3-3">&#91;3&#93;</a></sup><sup id="cite_ref-cruz5_5-9" class="reference"><a href="#cite_note-cruz5-5">&#91;5&#93;</a></sup>
</p>
<h3><span id="Argon/Nd:YAG-KTP_532_nm_or_solid-state_Laser"></span><span class="mw-headline" id="Argon.2FNd:YAG-KTP_532_nm_or_solid-state_Laser">Argon/Nd:YAG-KTP 532 nm or solid-state Laser</span></h3>
<p>Nd:YAG-KTP 532 nm and solid-state lasers produce thermal (coagulative) effects with lower energies at higher exposures or explosive effects (vaporization) if higher energies are used. Unlike Nd:YAG, these lasers require pigment for light energy absorption and therefore need more adjustments and greater variety in techniques and laser parameters to iris pigment density posterior to the stroma. Sequential Nd:YAG-KTP 532nm/Nd:YAG LPI can be useful in patients with thick brown irides, particularly in East Asian and African populations. Nd:YAG-KTP 532 nm laser pre-treatment to thin the iris results in lower energy needed with the Nd:YAG laser, which is then used to penetrate the iris and create an iridotomy. By using only a fraction of the power required for pure YAG laser iridotomy, it is more efficient and carries a lower risk of complications, namely anterior chamber hemorrhage.<sup id="cite_ref-lam3_3-7" class="reference"><a href="#cite_note-lam3-3">&#91;3&#93;</a></sup><sup id="cite_ref-cruz5_5-10" class="reference"><a href="#cite_note-cruz5-5">&#91;5&#93;</a></sup>
</p><p><a href="/File:Argon_laser_parameters.png" class="image"><img alt="Argon laser parameters.png" src="/w/images/1/thumb/1/19/Argon_laser_parameters.png/690px-Argon_laser_parameters.png" decoding="async" width="690" height="388" srcset="/w/images/1/1/19/Argon_laser_parameters.png 1.5x" /></a>
</p>
<h3><span class="mw-headline" id="Nd:YAG_laser_iridotomy">Nd:YAG laser iridotomy</span></h3>
<p>The Q-switched Nd:YAG lasers rely on tissue photodisruption to create a rapidly expanding ionic plasma wave and thus is efficient in all iris colours. The subsequent shock-wave and mainly cavitation bubble will in turn mechanically burst through the stromal tissue. The Nd:YAG laser is preferred by many surgeons because it perforates the iris easily, requiring lower energy than Nd:YAG-KTP 532 nm lasers. It is easier to penetrate dark brown irides with these devices because the former have a tendency to absorb too much energy during treatment, and pale irides absorb laser energy poorly. Moreover, Nd: YAG iridotomies may be less likely to close over time.<sup id="cite_ref-bMJ1_1-17" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup><sup id="cite_ref-lam3_3-8" class="reference"><a href="#cite_note-lam3-3">&#91;3&#93;</a></sup><sup id="cite_ref-cruz5_5-11" class="reference"><a href="#cite_note-cruz5-5">&#91;5&#93;</a></sup><sup id="cite_ref-robin9_9-1" class="reference"><a href="#cite_note-robin9-9">&#91;9&#93;</a></sup><sup id="cite_ref-pollack25_24-0" class="reference"><a href="#cite_note-pollack25-24">&#91;24&#93;</a></sup>
</p><p><a href="/File:YAG.png" class="image"><img alt="YAG.png" src="/w/images/1/thumb/d/da/YAG.png/690px-YAG.png" decoding="async" width="690" height="388" srcset="/w/images/1/d/da/YAG.png 1.5x" /></a>
</p>
<h2><span class="mw-headline" id="Complications">Complications</span></h2>
<h3><span class="mw-headline" id="1._Transient_Increase_in_IOP">1. Transient Increase in IOP</span></h3>
<p>Acute onset IOP elevation after LPI is the most common postoperative complication following LPI. It is usually transient, occurring most frequently in the first 4 hours after treatment. At least an 8 mmHg increase from baseline has been reported in 6% to 10% of patients and an IOP superior to 21 mmHg in 2% to 72%.<sup id="cite_ref-bMJ1_1-18" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup><sup id="cite_ref-radhakrishnan26_25-0" class="reference"><a href="#cite_note-radhakrishnan26-25">&#91;25&#93;</a></sup> Its occurrence as a primary event is thought to be caused by obstruction of the trabecular meshwork by released blood, iris pigment and other debris.<sup id="cite_ref-cruz5_5-12" class="reference"><a href="#cite_note-cruz5-5">&#91;5&#93;</a></sup> Plateau iris syndrome or other non-pupillary block angle closure mechanism, inflammation, extensive peripheral anterior synechiae (PAS) and prolonged corticosteroid therapy are possible secondary causes of IOP elevation post-procedure.
Prophylaxis with pressure-lowering agents is an effective strategy to prevent IOP rise after the procedure.<sup id="cite_ref-bMJ1_1-19" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup><sup id="cite_ref-kumar12_12-1" class="reference"><a href="#cite_note-kumar12-12">&#91;12&#93;</a></sup>
</p>
<h3><span id="2._Anterior_Chamber_Bleeding_(Hyphema)"></span><span class="mw-headline" id="2._Anterior_Chamber_Bleeding_.28Hyphema.29">2. Anterior Chamber Bleeding (Hyphema)</span></h3>
<p>Ii is a common complication post-LPI. It refers to bleeding from the iridotomy site, is minor in most cases and can usually be stopped by light pressure applied to the eye with the contact lens. The incidence and severity of anterior chamber bleeding has been reported to be similar whether the patient was on or off antithrombotic therapy (i.e. aspirin, clopidogrel, warfarin) and between groups taking different antithrombotic medications. Therefore, antiaggregants and anticoagulants need not be discontinued before LPI, and specific patients may have a bleeding diathesis regardless of the medications taken.<sup id="cite_ref-radhakrishnan26_25-1" class="reference"><a href="#cite_note-radhakrishnan26-25">&#91;25&#93;</a></sup><sup id="cite_ref-arunmongkol27_26-0" class="reference"><a href="#cite_note-arunmongkol27-26">&#91;26&#93;</a></sup><sup id="cite_ref-golan28_27-0" class="reference"><a href="#cite_note-golan28-27">&#91;27&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="3._Visual_Dysphotopsias">3. Visual Dysphotopsias</span></h3>
<p>Visual symptoms are uncommon but known to occur after the procedure, which include blurring, glares, halos, lines, spots and shadows at a reported rate of 2% to 16&#160;%. <sup id="cite_ref-radhakrishnan26_25-2" class="reference"><a href="#cite_note-radhakrishnan26-25">&#91;25&#93;</a></sup>
Symptom rates according to LPI location are mixed across large studies. Although Spaeth et al.<sup id="cite_ref-spaeth29_28-0" class="reference"><a href="#cite_note-spaeth29-28">&#91;28&#93;</a></sup> report dysphotopsia symptoms after LPI in 9% of eyes with completely covered, 26% with partially covered and 17.5% with fully exposed iridotomies, a large trial by Srinivasan et al. reported no statistical difference of new visual symptoms according to LPI location (superior versus nasal or temporal) 2 weeks post-LPI.<sup id="cite_ref-srinivasan30_29-0" class="reference"><a href="#cite_note-srinivasan30-29">&#91;29&#93;</a></sup> The same group also found that the majority of visual symptoms were likely to resolve after 6 months of follow-up which may indicate that patients adapt or learn to ignore them.<sup id="cite_ref-kavitha31_30-0" class="reference"><a href="#cite_note-kavitha31-30">&#91;30&#93;</a></sup> Finally, temporal LPI have been reported to cause less visual symptoms versus superior LPIs.<sup id="cite_ref-radhakrishnan26_25-3" class="reference"><a href="#cite_note-radhakrishnan26-25">&#91;25&#93;</a></sup><sup id="cite_ref-vera32_31-0" class="reference"><a href="#cite_note-vera32-31">&#91;31&#93;</a></sup>
Therefore, patients complaining of newly-onset visual symptoms post-LPI can be reassured that improvement of symptoms may occur over time without active intervention. Tinted lenses have been used to relieve visual symptoms.<sup id="cite_ref-lam3_3-9" class="reference"><a href="#cite_note-lam3-3">&#91;3&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="4._Cataract_Progression">4. Cataract Progression</span></h3>
<p>The risk of a traumatic cataract has been reported to be increased in post-LPI subjects at follow-up periods ranging from 12 months to 6 years<sup id="cite_ref-vijaya11_11-1" class="reference"><a href="#cite_note-vijaya11-11">&#91;11&#93;</a></sup><sup id="cite_ref-radhakrishnan26_25-4" class="reference"><a href="#cite_note-radhakrishnan26-25">&#91;25&#93;</a></sup><sup id="cite_ref-tan33_32-0" class="reference"><a href="#cite_note-tan33-32">&#91;32&#93;</a></sup><sup id="cite_ref-lim34_33-0" class="reference"><a href="#cite_note-lim34-33">&#91;33&#93;</a></sup>, and case reports of posterior subcapsular cataracts after LPI may be found in the literature.<sup id="cite_ref-lam3_3-10" class="reference"><a href="#cite_note-lam3-3">&#91;3&#93;</a></sup>Postulated mechanisms include direct damage to the crystalline lens, altered aqueous fluid dynamics and mild inflammatory changes to the iris which may induce metabolic changes that accelerate cataract formation.<sup id="cite_ref-cruz5_5-13" class="reference"><a href="#cite_note-cruz5-5">&#91;5&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="5._Iridotomy_closure_and_necessity_for_repeat_LPI">5. Iridotomy closure and necessity for repeat LPI</span></h3>
<p>Closure of the iridotomy has been reported to occur at a rate between 1% at 2 weeks to 20% within the first 6 months after the procedure, but the vast majority of iridotomies may remain patent years after the procedure.<sup id="cite_ref-radhakrishnan26_25-5" class="reference"><a href="#cite_note-radhakrishnan26-25">&#91;25&#93;</a></sup><sup id="cite_ref-waisbourd35_34-0" class="reference"><a href="#cite_note-waisbourd35-34">&#91;34&#93;</a></sup><sup id="cite_ref-jiang36_35-0" class="reference"><a href="#cite_note-jiang36-35">&#91;35&#93;</a></sup> This may occur due to accumulation of debris and pigment granules, although complete closure of the iridotomy is unusual with ND:Yag lasers. Repeat LPI can be performed at the same site immediately after the first procedure, a few hours later if debris impede the observation of the iridotomy or creating an iridotomy at another site. 
</p>
<h3><span class="mw-headline" id="6._Aqueous_misdirection_syndrome">6. Aqueous misdirection syndrome</span></h3>
<p>In rare cases, aqueous misdirection can complicate the management of primary angle-closure. This may occur following laser iridotomy and other surgical procedures. Forward movement of the lens iris diaphragm causes secondary angle-closure resulting in IOP elevation. These cases, typically have very small eyes (axial length &lt;21 mm) and higher hypermetropic refraction (&gt; +6D). It is believed that the ciliary processes come into contact with the lens equator, and/or a firm zonule/posterior capsule diaphragm, causing misdirection of aqueous into the vitreous.<sup id="cite_ref-bMJ1_1-20" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup>
Malignant glaucoma is a rare complication of laser iridotomy and should be considered in eyes with progressive anterior chamber shallowing and myopia despite normal IOP. 
</p>
<h3><span class="mw-headline" id="Other_complications">Other complications</span></h3>
<p>A reduction in endothelial cell count after LPI has been reported in the literature.<sup id="cite_ref-kumar12_12-2" class="reference"><a href="#cite_note-kumar12-12">&#91;12&#93;</a></sup><sup id="cite_ref-radhakrishnan26_25-6" class="reference"><a href="#cite_note-radhakrishnan26-25">&#91;25&#93;</a></sup> Postoperative inflammation is usually transient and mild, rarely resulting in posterior synechiae. Rare complications include sterile hypopyon, macular hole formation, cystoid macular oedema and retinal haemorrhages.<sup id="cite_ref-berger10_10-1" class="reference"><a href="#cite_note-berger10-10">&#91;10&#93;</a></sup><sup id="cite_ref-arunmongkol27_26-1" class="reference"><a href="#cite_note-arunmongkol27-26">&#91;26&#93;</a></sup><sup id="cite_ref-36" class="reference"><a href="#cite_note-36">&#91;36&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Outcomes">Outcomes</span></h2>
<h3><span class="mw-headline" id="1._IOP_control">1. IOP control</span></h3>
<p>The effectiveness of the procedure in controlling the IOP varies according to the staging of the disease, with earlier stages of the angle-closure spectrum reporting the highest success rates, while the prognosis is less favorable after an AAC crisis an even more guarded if glaucomatous optic nerve damage can be demonstrated. In fact, several studies regarding the spectrum of PAC report that 7.1%-28.0% of PACS eyes, 42.4%-80.0% PAC eyes and 83.3%-100% of PACG eyes required additional medical and/or surgical intervention after LPI.<sup id="cite_ref-cruz5_5-14" class="reference"><a href="#cite_note-cruz5-5">&#91;5&#93;</a></sup><sup id="cite_ref-peng37_37-0" class="reference"><a href="#cite_note-peng37-37">&#91;37&#93;</a></sup><sup id="cite_ref-rosman38_38-0" class="reference"><a href="#cite_note-rosman38-38">&#91;38&#93;</a></sup><sup id="cite_ref-chen39_39-0" class="reference"><a href="#cite_note-chen39-39">&#91;39&#93;</a></sup>
On the other hand, the EAGLE trial, which included PAC and PACG patients, showed that initial treatment with clear-lens extraction was superior to LPI  with topical medical treatment for participants with an IOP over 30 mmHg and primary angle closure or primary angle-closure glaucoma, with significantly fewer participants in the clear-lens extraction group needing additional treatment to control intraocular pressure and fewer glaucoma medications than patients who received standard care. The benefit of CLE in patients with PAC and an IOP inferior to 30 mmHg is unclear. Intraocular pressure was better with clear-lens extraction than with standard care, with the mean pressure being around 1 mm Hg lower in the clear-lens extraction group at 3 years.<sup id="cite_ref-radhakrishnan26_25-7" class="reference"><a href="#cite_note-radhakrishnan26-25">&#91;25&#93;</a></sup><sup id="cite_ref-azuarablanco40_40-0" class="reference"><a href="#cite_note-azuarablanco40-40">&#91;40&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="2._Anatomical_improvement">2. Anatomical improvement</span></h3>
<p>The effect of LPI on angle width has been evaluated across studies using a variety of quantitative and qualitative parameters. A large number of studies have demonstrated short-term increases in angle width across the PAC spectrum expressed as an increase in the Shaffer grade and an increase in quantitative angle-width parameters using UBM and AS-OCT.<sup id="cite_ref-radhakrishnan26_25-8" class="reference"><a href="#cite_note-radhakrishnan26-25">&#91;25&#93;</a></sup> However, two prospective studies have demonstrated a gradual and significant decrease in angle width after LPI was performed.<sup id="cite_ref-jiang18_18-1" class="reference"><a href="#cite_note-jiang18-18">&#91;18&#93;</a></sup><sup id="cite_ref-lee41_41-0" class="reference"><a href="#cite_note-lee41-41">&#91;41&#93;</a></sup>
Baseline anatomical factors associated with persistent angle closure after LPI include the presence of PAS, increased IOP, UBM parameters such as shallower peripheral angle width, thicker iris, and more anteriorly positioned ciliary body; and AS-OCT parameters such as greater mean lens vault and thicker iris. These factors represent a narrower angle before LPI and non-pupillary block mechanisms of angle closure.<sup id="cite_ref-radhakrishnan26_25-9" class="reference"><a href="#cite_note-radhakrishnan26-25">&#91;25&#93;</a></sup>
Indeed, LPI induces significant changes in the 3-D anterior segment morphology in primary angle closure suspect patients with an increase in central anterior chamber depth, anterior chamber volume and widening of the iridocorneal angle with no change in central corneal thickness, intraocular pressure or pupil diameter.<sup id="cite_ref-mansoori42_42-0" class="reference"><a href="#cite_note-mansoori42-42">&#91;42&#93;</a></sup>
LPI is more effective than pilocarpine in widening the iridocorneal angle without significant shallowing the anterior chamber in eyes with anatomically narrow angles.<sup id="cite_ref-mogil43_43-0" class="reference"><a href="#cite_note-mogil43-43">&#91;43&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="3._Prevention_of_AAC_crisis">3. Prevention of AAC crisis</span></h3>
<p>LPI has been shown in trials to prevent recurrent attacks of acute angle closure, with an effectiveness and safety equal to that of surgical iridectomy, and with better acceptability to patients.<sup id="cite_ref-schwenn44_44-0" class="reference"><a href="#cite_note-schwenn44-44">&#91;44&#93;</a></sup> Good effectiveness in preventing acute attacks in fellow eyes has also been reported.<sup id="cite_ref-ang16_16-1" class="reference"><a href="#cite_note-ang16-16">&#91;16&#93;</a></sup> Nonetheless, isolated reports do exist of eyes experiencing a recurrent acute attack after LPI.<sup id="cite_ref-lam3_3-11" class="reference"><a href="#cite_note-lam3-3">&#91;3&#93;</a></sup><sup id="cite_ref-tanasescu45_45-0" class="reference"><a href="#cite_note-tanasescu45-45">&#91;45&#93;</a></sup>
In AAC, laser iridotomy relieves the attack in most cases. Superior outcomes have been reported in Caucasian eyes than in Asian eyes<sup id="cite_ref-lam3_3-12" class="reference"><a href="#cite_note-lam3-3">&#91;3&#93;</a></sup>. In AAC attacks, significant amount of PAS, a higher presenting IOP, longer attack duration, poor initial response to therapy (&lt;30% IOP) and a larger C/D ratio, have been associated with inadequate long-term IOP control after LPI. These findings are consistent with a more severe disease affecting the ITC and the trabecular meshwork.<sup id="cite_ref-prum2_2-19" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup><sup id="cite_ref-lam3_3-13" class="reference"><a href="#cite_note-lam3-3">&#91;3&#93;</a></sup><sup id="cite_ref-radhakrishnan26_25-10" class="reference"><a href="#cite_note-radhakrishnan26-25">&#91;25&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="4._Disease_Progression">4. Disease Progression</span></h3>
<p>Progression from PACS to PAC was based on the development of PAS or elevated IOP. Progression from PACS or PAC to PACG was defined using both structural (disc appearance) and functional (visual field) criteria in most studies.<sup id="cite_ref-prum2_2-20" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup>
In the EAGLE cohort, visual acuity outcomes in the clear-lens extraction (CLE) group were similar to the LPI group.<sup id="cite_ref-day46_46-0" class="reference"><a href="#cite_note-day46-46">&#91;46&#93;</a></sup> In the EAGLE trial, CLE was superior to LPI in improving visual function. This improvement (eg, contrast sensitivity) may have resulted from eliminating mild age-related changes in lens transparency, and by correction of refractive error, which caused an improvement in good visual acuity without the need for spectacles. While this magnitude of change is unlikely to be clinically important, it points to the overall improvement in visual function associated with CLE. A recent systematic review found insufficient evidence based on randomized controlled trials as to whether iridotomy slows progression of visual field loss at one year compared to no iridotomy.<sup id="cite_ref-le47_47-0" class="reference"><a href="#cite_note-le47-47">&#91;47&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Summary">Summary</span></h2>
<p>LPI is an integral component in the management of PAC. Although LPI has been available since the 1970s, its role in the treatment algorithm for PAC is still under debate; questions such as who should be treated with an iridotomy and whether iridotomy prevents disease progression continue to be relevant today.<sup id="cite_ref-prum2_2-21" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup>
After LPI, most PACS subjects can expect to receive no further treatment. On the other hand, many PAC and APAC eyes, and most PACG eyes, need additional treatment to control IOP. LPI has a favorable effect on IOP, especially when extensive synechial closure or glaucomatous nerve damage have not occurred. Factors predictive for IOP elevation, or the need for further treatment after LPI, were those reflective of worse disease at baseline, such as higher IOP, greater cup-to-disc ratio, and greater synechial closure at presentation.<sup id="cite_ref-prum2_2-22" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup>
The safety and effectiveness of LPI for PAC/PACG has promoted a gradual widening of the criteria for iridotomy during the past couple of decades. However, more inclusive criteria spurred the debate over treatment algorithms, as we still do not know which eyes will develop glaucomatous damage, despite early manifestations of narrow angles, and offering iridotomy too soon would expose healthier patients to complications without clear evidence of benefit.<sup id="cite_ref-cruz5_5-15" class="reference"><a href="#cite_note-cruz5-5">&#91;5&#93;</a></sup>
More recently, the role of cataract extraction in the PAC disease spectrum has continued to fuel debate around LPI timing and its indications. In fact, the EAGLE recommends clear-lens extraction as first-line treatment for the subset of PAC patients with an IOP over 30 mmHg. Newer and more objective angle imaging devices are expected to contribute towards predicting the success of laser iridotomy in the future.<sup id="cite_ref-prum2_2-23" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup><sup id="cite_ref-cruz5_5-16" class="reference"><a href="#cite_note-cruz5-5">&#91;5&#93;</a></sup><sup id="cite_ref-azuarablanco40_40-1" class="reference"><a href="#cite_note-azuarablanco40-40">&#91;40&#93;</a></sup>
In conclusion, LPI increases angle width in all stages of PAC and has a favorable effect on IOP in eyes without extensive angle or disc damage. Although there is a gradual decrease in angle width in PACS eyes after LPI, further treatment after LPI in this subgroup is infrequent. In contrast, additional treatment after LPI is more likely in PAC, APAC, and PACG eyes, and they should be monitored for IOP elevation and progression to glaucoma.<sup id="cite_ref-bMJ1_1-21" class="reference"><a href="#cite_note-bMJ1-1">&#91;1&#93;</a></sup><sup id="cite_ref-prum2_2-24" class="reference"><a href="#cite_note-prum2-2">&#91;2&#93;</a></sup><sup id="cite_ref-international13_13-1" class="reference"><a href="#cite_note-international13-13">&#91;13&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="References">References</span></h2>
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-bMJ1-1"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-bMJ1_1-0">1.00</a></sup> <sup><a href="#cite_ref-bMJ1_1-1">1.01</a></sup> <sup><a href="#cite_ref-bMJ1_1-2">1.02</a></sup> <sup><a href="#cite_ref-bMJ1_1-3">1.03</a></sup> <sup><a href="#cite_ref-bMJ1_1-4">1.04</a></sup> <sup><a href="#cite_ref-bMJ1_1-5">1.05</a></sup> <sup><a href="#cite_ref-bMJ1_1-6">1.06</a></sup> <sup><a href="#cite_ref-bMJ1_1-7">1.07</a></sup> <sup><a href="#cite_ref-bMJ1_1-8">1.08</a></sup> <sup><a href="#cite_ref-bMJ1_1-9">1.09</a></sup> <sup><a href="#cite_ref-bMJ1_1-10">1.10</a></sup> <sup><a href="#cite_ref-bMJ1_1-11">1.11</a></sup> <sup><a href="#cite_ref-bMJ1_1-12">1.12</a></sup> <sup><a href="#cite_ref-bMJ1_1-13">1.13</a></sup> <sup><a href="#cite_ref-bMJ1_1-14">1.14</a></sup> <sup><a href="#cite_ref-bMJ1_1-15">1.15</a></sup> <sup><a href="#cite_ref-bMJ1_1-16">1.16</a></sup> <sup><a href="#cite_ref-bMJ1_1-17">1.17</a></sup> <sup><a href="#cite_ref-bMJ1_1-18">1.18</a></sup> <sup><a href="#cite_ref-bMJ1_1-19">1.19</a></sup> <sup><a href="#cite_ref-bMJ1_1-20">1.20</a></sup> <sup><a href="#cite_ref-bMJ1_1-21">1.21</a></sup></span> <span class="reference-text">BMJ Publishing Group Ltd. BMA House, Square T, London, 9jr W. European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Part 1Supported by the EGS Foundation. Br J Ophthalmol. BMJ Publishing Group Ltd; 2017;101: 1–72.</span>
</li>
<li id="cite_note-prum2-2"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-prum2_2-0">2.00</a></sup> <sup><a href="#cite_ref-prum2_2-1">2.01</a></sup> <sup><a href="#cite_ref-prum2_2-2">2.02</a></sup> <sup><a href="#cite_ref-prum2_2-3">2.03</a></sup> <sup><a href="#cite_ref-prum2_2-4">2.04</a></sup> <sup><a href="#cite_ref-prum2_2-5">2.05</a></sup> <sup><a href="#cite_ref-prum2_2-6">2.06</a></sup> <sup><a href="#cite_ref-prum2_2-7">2.07</a></sup> <sup><a href="#cite_ref-prum2_2-8">2.08</a></sup> <sup><a href="#cite_ref-prum2_2-9">2.09</a></sup> <sup><a href="#cite_ref-prum2_2-10">2.10</a></sup> <sup><a href="#cite_ref-prum2_2-11">2.11</a></sup> <sup><a href="#cite_ref-prum2_2-12">2.12</a></sup> <sup><a href="#cite_ref-prum2_2-13">2.13</a></sup> <sup><a href="#cite_ref-prum2_2-14">2.14</a></sup> <sup><a href="#cite_ref-prum2_2-15">2.15</a></sup> <sup><a href="#cite_ref-prum2_2-16">2.16</a></sup> <sup><a href="#cite_ref-prum2_2-17">2.17</a></sup> <sup><a href="#cite_ref-prum2_2-18">2.18</a></sup> <sup><a href="#cite_ref-prum2_2-19">2.19</a></sup> <sup><a href="#cite_ref-prum2_2-20">2.20</a></sup> <sup><a href="#cite_ref-prum2_2-21">2.21</a></sup> <sup><a href="#cite_ref-prum2_2-22">2.22</a></sup> <sup><a href="#cite_ref-prum2_2-23">2.23</a></sup> <sup><a href="#cite_ref-prum2_2-24">2.24</a></sup></span> <span class="reference-text">Prum BE Jr, Herndon LW Jr, Moroi SE, Mansberger SL, Stein JD, Lim MC, et al. Primary Angle Closure Preferred Practice Pattern(®) Guidelines. Ophthalmology. 2016;123: P1–P40.</span>
</li>
<li id="cite_note-lam3-3"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-lam3_3-0">3.00</a></sup> <sup><a href="#cite_ref-lam3_3-1">3.01</a></sup> <sup><a href="#cite_ref-lam3_3-2">3.02</a></sup> <sup><a href="#cite_ref-lam3_3-3">3.03</a></sup> <sup><a href="#cite_ref-lam3_3-4">3.04</a></sup> <sup><a href="#cite_ref-lam3_3-5">3.05</a></sup> <sup><a href="#cite_ref-lam3_3-6">3.06</a></sup> <sup><a href="#cite_ref-lam3_3-7">3.07</a></sup> <sup><a href="#cite_ref-lam3_3-8">3.08</a></sup> <sup><a href="#cite_ref-lam3_3-9">3.09</a></sup> <sup><a href="#cite_ref-lam3_3-10">3.10</a></sup> <sup><a href="#cite_ref-lam3_3-11">3.11</a></sup> <sup><a href="#cite_ref-lam3_3-12">3.12</a></sup> <sup><a href="#cite_ref-lam3_3-13">3.13</a></sup></span> <span class="reference-text">Lam DSC, Tham CCY, Congdon NG, Baig N. Peripheral Iridotomy for Angle-Closure Glaucoma. Glaucoma. Elsevier; 2015. pp. 708–715.</span>
</li>
<li id="cite_note-gr.C3.A4fe4-4"><span class="mw-cite-backlink"><a href="#cite_ref-gr.C3.A4fe4_4-0">↑</a></span> <span class="reference-text">Gräfe A. Ueber die Iridectomie bei Glaucom und über den glaucomatösen Process [Internet]. Albrecht von Graefes Archiv für Ophthalmologie. 1857. pp. 456–555. doi:10.1007/bf02720732</span>
</li>
<li id="cite_note-cruz5-5"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-cruz5_5-0">5.00</a></sup> <sup><a href="#cite_ref-cruz5_5-1">5.01</a></sup> <sup><a href="#cite_ref-cruz5_5-2">5.02</a></sup> <sup><a href="#cite_ref-cruz5_5-3">5.03</a></sup> <sup><a href="#cite_ref-cruz5_5-4">5.04</a></sup> <sup><a href="#cite_ref-cruz5_5-5">5.05</a></sup> <sup><a href="#cite_ref-cruz5_5-6">5.06</a></sup> <sup><a href="#cite_ref-cruz5_5-7">5.07</a></sup> <sup><a href="#cite_ref-cruz5_5-8">5.08</a></sup> <sup><a href="#cite_ref-cruz5_5-9">5.09</a></sup> <sup><a href="#cite_ref-cruz5_5-10">5.10</a></sup> <sup><a href="#cite_ref-cruz5_5-11">5.11</a></sup> <sup><a href="#cite_ref-cruz5_5-12">5.12</a></sup> <sup><a href="#cite_ref-cruz5_5-13">5.13</a></sup> <sup><a href="#cite_ref-cruz5_5-14">5.14</a></sup> <sup><a href="#cite_ref-cruz5_5-15">5.15</a></sup> <sup><a href="#cite_ref-cruz5_5-16">5.16</a></sup></span> <span class="reference-text">Cruz, M. 2017. III. Laser Surgery in Glaucoma: 19. LASER Iridotomy. In Laser Manual in Ophthalmology – Fundamentals and Laser Clinical Practice, ed. J. Henriques, A. Duarte, T. Quintão, 115 - 122. ISBN: 978-989-20-7147-3. Lisbon: Medical Laser Interdisciplinary Portuguese Society.</span>
</li>
<li id="cite_note-khuri6-6"><span class="mw-cite-backlink"><a href="#cite_ref-khuri6_6-0">↑</a></span> <span class="reference-text">Khuri CH. Argon laser iridectomies. Am J Ophthalmol. 1973;76: 490–493.</span>
</li>
<li id="cite_note-palanker7-7"><span class="mw-cite-backlink"><a href="#cite_ref-palanker7_7-0">↑</a></span> <span class="reference-text">Palanker DV. Fifty Years of Ophthalmic Laser Therapy [Internet]. Archives of Ophthalmology. 2011. p. 1613. doi:10.1001/archophthalmol.2011.293</span>
</li>
<li id="cite_note-quigley8-8"><span class="mw-cite-backlink"><a href="#cite_ref-quigley8_8-0">↑</a></span> <span class="reference-text">Quigley HA. Long-term follow-up of laser iridotomy. Ophthalmology. 1981;88: 218–224.</span>
</li>
<li id="cite_note-robin9-9"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-robin9_9-0">9.0</a></sup> <sup><a href="#cite_ref-robin9_9-1">9.1</a></sup></span> <span class="reference-text">Robin AL, Pollack IP. A Comparison of Neodymium:YAG and Argon Laser Iridotomies. Ophthalmology. 1984;91: 1011–1016.</span>
</li>
<li id="cite_note-berger10-10"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-berger10_10-0">10.0</a></sup> <sup><a href="#cite_ref-berger10_10-1">10.1</a></sup></span> <span class="reference-text">Berger BB. Foveal photocoagulation from laser iridotomy. Ophthalmology. 1984;91: 1029–1033.</span>
</li>
<li id="cite_note-vijaya11-11"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-vijaya11_11-0">11.0</a></sup> <sup><a href="#cite_ref-vijaya11_11-1">11.1</a></sup></span> <span class="reference-text">Vijaya L, Asokan R, Panday M, George R. Is prophylactic laser peripheral iridotomy for primary angle closure suspects a risk factor for cataract progression? The Chennai Eye Disease Incidence Study. Br J Ophthalmol. 2017;101: 665–670.</span>
</li>
<li id="cite_note-kumar12-12"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-kumar12_12-0">12.0</a></sup> <sup><a href="#cite_ref-kumar12_12-1">12.1</a></sup> <sup><a href="#cite_ref-kumar12_12-2">12.2</a></sup></span> <span class="reference-text">Kumar RS, Baskaran M, Friedman DS, Xu Y, Wong H-T, Lavanya R, et al. Effect of prophylactic laser iridotomy on corneal endothelial cell density over 3 years in primary angle closure suspects. Br J Ophthalmol. 2013;97: 258–261.</span>
</li>
<li id="cite_note-international13-13"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-international13_13-0">13.0</a></sup> <sup><a href="#cite_ref-international13_13-1">13.1</a></sup></span> <span class="reference-text">International Council of Ophthalmology&#160;: Enhancing Eye Care&#160;: Glaucoma [Internet]. [cited 1 Jun 2019]. Available: <a rel="nofollow" class="external free" href="http://www.icoph.org/enhancing_eyecare/glaucoma.html">http://www.icoph.org/enhancing_eyecare/glaucoma.html</a></span>
</li>
<li id="cite_note-lowe14-14"><span class="mw-cite-backlink"><a href="#cite_ref-lowe14_14-0">↑</a></span> <span class="reference-text">Lowe RF. Acute Angle-Closure Glaucoma: The second eye: An analysis of 200 cases. Br J Ophthalmol. 1962;46: 641–650.</span>
</li>
<li id="cite_note-bain15-15"><span class="mw-cite-backlink"><a href="#cite_ref-bain15_15-0">↑</a></span> <span class="reference-text">Bain WE. The fellow eye in acute closed-angle glaucoma. Br J Ophthalmol. 1957;41: 193–199.</span>
</li>
<li id="cite_note-ang16-16"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-ang16_16-0">16.0</a></sup> <sup><a href="#cite_ref-ang16_16-1">16.1</a></sup></span> <span class="reference-text">Ang LP, Aung T, Chew PT. Acute primary angle closure in an Asian population: long-term outcome of the fellow eye after prophylactic laser peripheral iridotomy. Ophthalmology. 2000;107: 2092–2096.</span>
</li>
<li id="cite_note-wilensky17-17"><span class="mw-cite-backlink"><a href="#cite_ref-wilensky17_17-0">↑</a></span> <span class="reference-text">Wilensky JT, Kaufman PL, Frohlichstein D, Gieser DK, Kass MA, Ritch R, et al. Follow-up of angle-closure glaucoma suspects. Am J Ophthalmol. 1993;115: 338–346.</span>
</li>
<li id="cite_note-jiang18-18"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-jiang18_18-0">18.0</a></sup> <sup><a href="#cite_ref-jiang18_18-1">18.1</a></sup></span> <span class="reference-text">Jiang Y, Chang DS, Zhu H, Khawaja AP, Aung T, Huang S, et al. Longitudinal changes of angle configuration in primary angle-closure suspects: the Zhongshan Angle-Closure Prevention Trial. Ophthalmology. 2014;121: 1699–1705.</span>
</li>
<li id="cite_note-weinreb19-19"><span class="mw-cite-backlink"><a href="#cite_ref-weinreb19_19-0">↑</a></span> <span class="reference-text">Weinreb RN, Moghimi S. Prophylactic laser iridotomy in primary angle-closure suspects. Lancet. 2019;393: 1572–1574.</span>
</li>
<li id="cite_note-weinreb20-20"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-weinreb20_20-0">20.0</a></sup> <sup><a href="#cite_ref-weinreb20_20-1">20.1</a></sup></span> <span class="reference-text">Weinreb RN, Friedman DS. Angle Closure and Angle Closure Glaucoma: Reports and Consensus Statements of the 3rd Global AIGS Consensus Meeting on Angle Closure Glaucoma. Kugler Publications; 2006.</span>
</li>
<li id="cite_note-michelessi21-21"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-michelessi21_21-0">21.0</a></sup> <sup><a href="#cite_ref-michelessi21_21-1">21.1</a></sup></span> <span class="reference-text">Michelessi M, Lindsley K. Peripheral iridotomy for pigmentary glaucoma. Cochrane Database Syst Rev. 2016;2: CD005655.</span>
</li>
<li id="cite_note-buffault22-22"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-buffault22_22-0">22.0</a></sup> <sup><a href="#cite_ref-buffault22_22-1">22.1</a></sup></span> <span class="reference-text">Buffault J, Leray B, Bouillot A, Baudouin C, Labbé A. Role of laser peripheral iridotomy in pigmentary glaucoma and pigment dispersion syndrome: A review of the literature [Internet]. Journal Français d’Ophtalmologie. 2017. pp. e315–e321. doi:10.1016/j.jfo.2017.09.002</span>
</li>
<li id="cite_note-kumar24-23"><span class="mw-cite-backlink"><a href="#cite_ref-kumar24_23-0">↑</a></span> <span class="reference-text">Kumar RS, Tantisevi V, Wong MH, Laohapojanart K, Chansanti O, Quek DT, et al. Plateau iris in Asian subjects with primary angle closure glaucoma. Arch Ophthalmol. 2009;127: 1269–1272.</span>
</li>
<li id="cite_note-pollack25-24"><span class="mw-cite-backlink"><a href="#cite_ref-pollack25_24-0">↑</a></span> <span class="reference-text">Pollack IP, Robin AL, Dragon DM, Green WR, Quigley HA, Murray TG, et al. Use of the neodymium:YAG laser to create iridotomies in monkeys and humans. Trans Am Ophthalmol Soc. 1984;82: 307–328.</span>
</li>
<li id="cite_note-radhakrishnan26-25"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-radhakrishnan26_25-0">25.00</a></sup> <sup><a href="#cite_ref-radhakrishnan26_25-1">25.01</a></sup> <sup><a href="#cite_ref-radhakrishnan26_25-2">25.02</a></sup> <sup><a href="#cite_ref-radhakrishnan26_25-3">25.03</a></sup> <sup><a href="#cite_ref-radhakrishnan26_25-4">25.04</a></sup> <sup><a href="#cite_ref-radhakrishnan26_25-5">25.05</a></sup> <sup><a href="#cite_ref-radhakrishnan26_25-6">25.06</a></sup> <sup><a href="#cite_ref-radhakrishnan26_25-7">25.07</a></sup> <sup><a href="#cite_ref-radhakrishnan26_25-8">25.08</a></sup> <sup><a href="#cite_ref-radhakrishnan26_25-9">25.09</a></sup> <sup><a href="#cite_ref-radhakrishnan26_25-10">25.10</a></sup></span> <span class="reference-text">Radhakrishnan S, Chen PP, Junk AK, Nouri-Mahdavi K, Chen TC. Laser Peripheral Iridotomy in Primary Angle Closure: A Report by the American Academy of Ophthalmology. Ophthalmology. 2018;125: 1110–1120.</span>
</li>
<li id="cite_note-arunmongkol27-26"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-arunmongkol27_26-0">26.0</a></sup> <sup><a href="#cite_ref-arunmongkol27_26-1">26.1</a></sup></span> <span class="reference-text">Arunmongkol S, Suwan Y, Supakontanasan W, Nilphatanakorn S, Teekhasaenee C. Eight-ball hyphema after laser iridotomy in a patient with undiagnosed hypocellular myelodysplastic syndrome. Int Med Case Rep J. 2018;11: 133–137.</span>
</li>
<li id="cite_note-golan28-27"><span class="mw-cite-backlink"><a href="#cite_ref-golan28_27-0">↑</a></span> <span class="reference-text">Golan S, Levkovitch-Verbin H, Shemesh G, Kurtz S. Anterior chamber bleeding after laser peripheral iridotomy. JAMA Ophthalmol. 2013;131: 626–629.</span>
</li>
<li id="cite_note-spaeth29-28"><span class="mw-cite-backlink"><a href="#cite_ref-spaeth29_28-0">↑</a></span> <span class="reference-text">Spaeth GL, Idowu O, Seligsohn A, Henderer J, Fonatanarosa J, Modi A, et al. The effects of iridotomy size and position on symptoms following laser peripheral iridotomy [Internet]. American Journal of Ophthalmology. 2006. pp. 427–428. doi:10.1016/j.ajo.2006.01.006</span>
</li>
<li id="cite_note-srinivasan30-29"><span class="mw-cite-backlink"><a href="#cite_ref-srinivasan30_29-0">↑</a></span> <span class="reference-text">Srinivasan K, Zebardast N, Krishnamurthy P, Abdul Kader M, Raman GV, Rajendrababu S, et al. Comparison of New Visual Disturbances after Superior versus Nasal/Temporal Laser Peripheral Iridotomy: A Prospective Randomized Trial. Ophthalmology. 2018;125: 345–351.</span>
</li>
<li id="cite_note-kavitha31-30"><span class="mw-cite-backlink"><a href="#cite_ref-kavitha31_30-0">↑</a></span> <span class="reference-text">Kavitha S, Ramulu PY, Venkatesh R, Palaniswamy K, Kader MA, Raman GV, et al. Resolution of Visual Dysphotopsias after Laser Iridotomy: Six-Month Follow-up. Ophthalmology. 2019;126: 469–471.e1.</span>
</li>
<li id="cite_note-vera32-31"><span class="mw-cite-backlink"><a href="#cite_ref-vera32_31-0">↑</a></span> <span class="reference-text">Vera V, Naqi A, Belovay GW, Varma DK, Ahmed IIK. Dysphotopsia after temporal versus superior laser peripheral iridotomy: a prospective randomized paired eye trial. Am J Ophthalmol. 2014;157: 929–935.</span>
</li>
<li id="cite_note-tan33-32"><span class="mw-cite-backlink"><a href="#cite_ref-tan33_32-0">↑</a></span> <span class="reference-text">Tan AM, Loon SC, Chew PTK. Outcomes following acute primary angle closure in an Asian population. Clin Experiment Ophthalmol. 2009;37: 467–472.</span>
</li>
<li id="cite_note-lim34-33"><span class="mw-cite-backlink"><a href="#cite_ref-lim34_33-0">↑</a></span> <span class="reference-text">Lim LS, Husain R, Gazzard G, Seah SKL, Aung T. Cataract progression after prophylactic laser peripheral iridotomy: potential implications for the prevention of glaucoma blindness. Ophthalmology. 2005;112: 1355–1359.</span>
</li>
<li id="cite_note-waisbourd35-34"><span class="mw-cite-backlink"><a href="#cite_ref-waisbourd35_34-0">↑</a></span> <span class="reference-text">Waisbourd M, Shafa A, Delvadia R, Sembhi H, Molineaux J, Henderer J, et al. Bilateral Same-day Laser Peripheral Iridotomy in the Philadelphia Glaucoma Detection and Treatment Project. J Glaucoma. 2016;25: e821–e825.</span>
</li>
<li id="cite_note-jiang36-35"><span class="mw-cite-backlink"><a href="#cite_ref-jiang36_35-0">↑</a></span> <span class="reference-text">Jiang Y, Chang DS, Foster PJ, He M, Huang S, Aung T, et al. Immediate changes in intraocular pressure after laser peripheral iridotomy in primary angle-closure suspects. Ophthalmology. 2012;119: 283–288.</span>
</li>
<li id="cite_note-36"><span class="mw-cite-backlink"><a href="#cite_ref-36">↑</a></span> <span class="reference-text">Tsui JC, Marks SJ. Unilateral Stage 1A Macular Hole Secondary to Low-Energy Nd:YAG Peripheral Iridotomy. <i>Cureus</i>. 2021;13(1):e12603. Published 2021 Jan 10. doi:10.7759/cureus.12603</span>
</li>
<li id="cite_note-peng37-37"><span class="mw-cite-backlink"><a href="#cite_ref-peng37_37-0">↑</a></span> <span class="reference-text">Peng P-H, Nguyen H, Lin H-S, Nguyen N, Lin S. Long-term outcomes of laser iridotomy in Vietnamese patients with primary angle closure. Br J Ophthalmol. 2011;95: 1207–1211.</span>
</li>
<li id="cite_note-rosman38-38"><span class="mw-cite-backlink"><a href="#cite_ref-rosman38_38-0">↑</a></span> <span class="reference-text">Rosman M, Aung T, Ang LPK, Chew PTK, Liebmann JM, Ritch R. Chronic angle-closure with glaucomatous damage: long-term clinical course in a North American population and comparison with an Asian population. Ophthalmology. 2002;109: 2227–2231.</span>
</li>
<li id="cite_note-chen39-39"><span class="mw-cite-backlink"><a href="#cite_ref-chen39_39-0">↑</a></span> <span class="reference-text">Chen M-J, Cheng C-Y, Chou C-K, Liu CJL, Hsu W-M. The long-term effect of Nd:YAG laser iridotomy on intraocular pressure in Taiwanese eyes with primary angle-closure glaucoma. J Chin Med Assoc. 2008;71: 300–304.</span>
</li>
<li id="cite_note-azuarablanco40-40"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-azuarablanco40_40-0">40.0</a></sup> <sup><a href="#cite_ref-azuarablanco40_40-1">40.1</a></sup></span> <span class="reference-text">Azuara-Blanco A, Burr J, Ramsay C, Cooper D, Foster PJ, Friedman DS, et al. Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial. Lancet. 2016;388: 1389–1397.</span>
</li>
<li id="cite_note-lee41-41"><span class="mw-cite-backlink"><a href="#cite_ref-lee41_41-0">↑</a></span> <span class="reference-text">Lee KS, Sung KR, Shon K, Sun JH, Lee JR. Longitudinal changes in anterior segment parameters after laser peripheral iridotomy assessed by anterior segment optical coherence tomography. Invest Ophthalmol Vis Sci. 2013;54: 3166–3170.</span>
</li>
<li id="cite_note-mansoori42-42"><span class="mw-cite-backlink"><a href="#cite_ref-mansoori42_42-0">↑</a></span> <span class="reference-text">Mansoori T, Balakrishna N. Anterior segment morphology after laser iridotomy in primary angle closure suspects. Clin Exp Optom. 2018;101: 333–338.</span>
</li>
<li id="cite_note-mogil43-43"><span class="mw-cite-backlink"><a href="#cite_ref-mogil43_43-0">↑</a></span> <span class="reference-text">Mogil RS, Khezri N, Ren R, Adleyba O, Abumasmah R, Ghassibi MP, et al. Changes in Iridocorneal Angle and Anterior Chamber Structure in Eyes With Anatomically Narrow Angles: Laser Iridotomy Versus Pilocarpine. J Glaucoma. 2018;27: 1073–1078.</span>
</li>
<li id="cite_note-schwenn44-44"><span class="mw-cite-backlink"><a href="#cite_ref-schwenn44_44-0">↑</a></span> <span class="reference-text">Schwenn O, Sell F, Pfeiffer N, Grehn F. Prophylactic Nd:YAG-laser iridotomy versus surgical iridectomy: a randomized, prospective study. Ger J Ophthalmol. 1995;4: 374–379.</span>
</li>
<li id="cite_note-tanasescu45-45"><span class="mw-cite-backlink"><a href="#cite_ref-tanasescu45_45-0">↑</a></span> <span class="reference-text">Tanasescu I, Grehn F. Acute angle-closure glaucoma despite previous Nd: YAG laser iridotomy: a report on 13 cases. Ophthalmologe. 2003;100: 832–835.</span>
</li>
<li id="cite_note-day46-46"><span class="mw-cite-backlink"><a href="#cite_ref-day46_46-0">↑</a></span> <span class="reference-text">Day AC, Cooper D, Burr J, Foster PJ, Friedman DS, Gazzard G, et al. Clear lens extraction for the management of primary angle closure glaucoma: surgical technique and refractive outcomes in the EAGLE cohort. Br J Ophthalmol. 2018;102: 1658–1662.</span>
</li>
<li id="cite_note-le47-47"><span class="mw-cite-backlink"><a href="#cite_ref-le47_47-0">↑</a></span> <span class="reference-text">Le JT, Rouse B, Gazzard G. Iridotomy to slow progression of visual field loss in angle-closure glaucoma. Cochrane Database Syst Rev. 2018;6: CD012270.</span>
</li>
</ol></div>
<!-- 
NewPP limit report
Cached time: 20230306035156
Cache expiry: 86400
Dynamic content: false
Complications: [my_variables_no_cache]
[SMW] In‐text annotation parser time: 0.001 seconds
CPU time usage: 0.342 seconds
Real time usage: 2.346 seconds
Preprocessor visited node count: 1538/1000000
Post‐expand include size: 5963/2097152 bytes
Template argument size: 1432/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 0/100
Unstrip recursion depth: 0/20
Unstrip post‐expand size: 36103/5000000 bytes
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%  418.332      1 Template:Article
100.00%  418.332      1 -total
 96.89%  405.336      4 Template:Infobox_section
 46.05%  192.647      9 Template:UserLookup
  1.02%    4.285      1 Template:Review_expired
  0.32%    1.332      1 Template:Get_active_contest
  0.20%    0.827      1 Template:Infobox_begin
  0.19%    0.811      1 Template:Infobox_end
-->
</div></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://eyewiki.org/w/index.php?title=Laser_Peripheral_Iridotomy&amp;oldid=87678">https://eyewiki.org/w/index.php?title=Laser_Peripheral_Iridotomy&amp;oldid=87678</a>"</div>

						<!-- end body text -->
						<!-- data blocks which should go somewhere after the body text, but not before the catlinks block-->
						<div id='mw-data-after-content'>
	<div class="mw-cookiewarning-container"><div class="mw-cookiewarning-text"><span>The Academy uses cookies to analyze performance and provide relevant personalized content to users of our website.</span></div><form method="POST"><div class='oo-ui-layout oo-ui-horizontalLayout'><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-progressive oo-ui-buttonWidget'><a role='button' tabindex='0' aria-disabled='false' href='https://www.aao.org/privacy-policy' rel='nofollow' class='oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-progressive'></span><span class='oo-ui-labelElement-label'>Learn more</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-progressive'></span></a></span><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-inputWidget oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-primary oo-ui-flaggedElement-progressive oo-ui-buttonInputWidget'><button type='submit' tabindex='0' aria-disabled='false' name='disablecookiewarning' value='OK' class='oo-ui-inputWidget-input oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-invert'></span><span class='oo-ui-labelElement-label'>Accept</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-invert'></span></button></span></div></form></div>
</div>

					</div>
					<!-- category links -->
					<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/Special:Categories" title="Special:Categories">Categories</a>: <ul><li><a href="/Category:Articles" title="Category:Articles">Articles</a></li><li><a href="/Category:Glaucoma" title="Category:Glaucoma">Glaucoma</a></li></ul></div></div>
				</div>
			</div>
		</div>
	</div>
	<div class="mb-2 mt-4 footer container">
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar not-collapsible small mb-2" role="navigation" id="mw-navigation-hbpzywilid">
					<div class="navbar-nav">
					<!-- toolbox -->
					<div id="t-whatlinkshere" class="nav-item"><a href="/Special:WhatLinksHere/Laser_Peripheral_Iridotomy" title="A list of all wiki pages that link here [j]" accesskey="j" class="nav-link t-whatlinkshere">What links here</a></div>
					<div id="t-recentchangeslinked" class="nav-item"><a href="/Special:RecentChangesLinked/Laser_Peripheral_Iridotomy" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k" class="nav-link t-recentchangeslinked">Related changes</a></div>
					<div id="t-specialpages" class="nav-item"><a href="/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q" class="nav-link t-specialpages">Special pages</a></div>
					<div id="t-print" class="nav-item"><a href="javascript:print();" rel="alternate" title="Printable version of this page [p]" accesskey="p" class="nav-link t-print">Printable version</a></div>
					<div id="t-permalink" class="nav-item"><a href="/w/index.php?title=Laser_Peripheral_Iridotomy&amp;oldid=87678" title="Permanent link to this revision of the page" class="nav-link t-permalink">Permanent link</a></div>
					<div id="t-info" class="nav-item"><a href="/w/index.php?title=Laser_Peripheral_Iridotomy&amp;action=info" title="More information about this page" class="nav-link t-info">Page information</a></div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- footer links -->
				<div id="footer-info" class="footer-info">
					<!-- info -->
					<div> This page was last edited on December 25, 2022, at 16:36.</div>
					<div>This page has been accessed 173,644 times.</div>
				</div>
				<!-- places -->
				<div id="footer-places" class="footer-places">
					<div><a href="/EyeWiki:Privacy_policy" title="EyeWiki:Privacy policy">Privacy policy</a></div>
					<div><a href="/EyeWiki:About" title="EyeWiki:About">About EyeWiki</a></div>
					<div><a href="/EyeWiki:General_disclaimer" title="EyeWiki:General disclaimer">Disclaimers</a></div>
				</div>
			</div>
			<div class="col">
				<!-- footer icons -->
				<div id="footer-icons" class="justify-content-end footer-icons">
					<!-- poweredby -->
					<div><a href="https://www.mediawiki.org/"><img src="/w/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/w/resources/assets/poweredby_mediawiki_132x47.png 1.5x, /w/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" loading="lazy"/></a></div>
					<div><a href="https://www.semantic-mediawiki.org/wiki/Semantic_MediaWiki"><img src="data:image/png;base64,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" alt="Powered by Semantic MediaWiki" class="smw-footer" width="88" height="31" loading="lazy"/></a></div>
				</div>
			</div>
		</div>
	</div>
<script src="https://www.googletagmanager.com/gtag/js?id=UA-64665049-1" async=""></script><script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-64665049-1', {});
</script>

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"smw":{"limitreport-intext-parsertime":0.001},"limitreport":{"cputime":"0.342","walltime":"2.346","ppvisitednodes":{"value":1538,"limit":1000000},"postexpandincludesize":{"value":5963,"limit":2097152},"templateargumentsize":{"value":1432,"limit":2097152},"expansiondepth":{"value":11,"limit":40},"expensivefunctioncount":{"value":0,"limit":100},"unstrip-depth":{"value":0,"limit":20},"unstrip-size":{"value":36103,"limit":5000000},"timingprofile":["100.00%  418.332      1 Template:Article","100.00%  418.332      1 -total"," 96.89%  405.336      4 Template:Infobox_section"," 46.05%  192.647      9 Template:UserLookup","  1.02%    4.285      1 Template:Review_expired","  0.32%    1.332      1 Template:Get_active_contest","  0.20%    0.827      1 Template:Infobox_begin","  0.19%    0.811      1 Template:Infobox_end"]},"cachereport":{"timestamp":"20230306035156","ttl":86400,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":3078});});</script></body>
</html>